CytoSorbents Corporation (OTCBB:CTSO) reached up 35.29% in morning trading to $.23 with 3M shares traded. CytoSorbents Corporation is a critical care focused therapeutic device company in clinical trials to treat severe sepsis, the end result of "overwhelming infection," with a novel blood purification device called CytoSorb™. CytoSorbents Corporation (OTC.BB:CTSO - News) announced today that it has achieved European CE Mark approval for its flagship product, CytoSorb™. This milestone certifies that CytoSorb™ has met the safety and label efficacy claim requirements of the European Medical Devices Directive and can now be sold in the European Union (E.U.) for human clinical use.
Synthesis Energy Systems, Inc. (Nasdaq:SYMX) reached up 41.46% in morning trading to $2.90 with 3M shares traded. Synthesis Energy Systems, Inc. (SES) provides technology, equipment and engineering services for the conversion of low rank, low cost coal and biomass feedstocks into energy and chemical products. Its strategy is to create value through providing technology and equipment in regions where low rank coals and biomass feedstocks can be profitably converted into high value products through its proprietary U-GAS® fluidized bed gasification technology, which SES licenses from the Gas Technology Institute. U-GAS® gasifies coal cost effectively, without many of the harmful emissions normally associated with coal combustion plants. Synthesis Energy Systems, Inc. (Nasdaq:SYMX - News) ("SES") announced today that it has signed an agreement with China Energy Industry Holding Group Co., Limited ("China Energy"), for a cash investment of approximately US$83.8 million to support the Company's business strategy in China, including project development and investment. China Energy, a Hong Kong based limited liability corporation, has been formed by Zhongjixuan Investment Management Ltd. ("ZJX") of Beijing for the purpose of investing in SES.
Nile Therapeutics, Inc. (Nasdaq:NLTX) reached up 34.43% in morning trading to $.82 with 590K shares traded. Nile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. Nile Therapeutics, Inc. (Nasdaq:NLTX - News today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Nile's post-acute development program for cenderitide, which has the goal of reducing cardiovascular mortality and cardiovascular re-hospitalization in the post-acute period in patients with acute decompensated heart failure.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
